Stage
Series A - II | AliveTotal Raised
$34MLast Raised
$16M | 15 yrs agoAbout Vivendy Therapeutics
Vivendy Therapeutics, a start-up pharmaceutical company founded in March 2006, is focused on the development of an enzyme replacement therapy (ERT) for the treatment of Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease
Vivendy Therapeutics Frequently Asked Questions (FAQ)
What is Vivendy Therapeutics's latest funding round?
Vivendy Therapeutics's latest funding round is Series A - II.
How much did Vivendy Therapeutics raise?
Vivendy Therapeutics raised a total of $34M.
Who are the investors of Vivendy Therapeutics?
Investors of Vivendy Therapeutics include Aescap Venture, TVM Capital, EQT Life Sciences and BioMedPartners.